Remove DNA Remove Pharma Companies Remove Reagent
article thumbnail

BioSpace Global Roundup, Oct. 15

The Pharma Data

Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Ltd of Japan.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

At Nurix, Dr. Hansen focuses on establishing the company’s DNA-encoded library technology platform for small molecule identification and leading the discovery organization. But in companies, you cannot do that. Now she says that she completely appreciates the focus of industry. You only do your own [specific] thing,” she says.